

News Release

Lonza Group Ltd
Muenchensteinerstrasse 38
CH-4002 Basel, Switzerland
www.lonza.com

Legal Disclaimer: Not for release, publication or distribution in the United States of America, Canada, Japan or Australia. The information contained herein does not constitute an offer of securities for sale in the United States, Canada, Australia or Japan. This press release includes information and warnings set out below regarding its content, use and distribution that should be carefully read and observed.

Polynt S.p.A. IPO price set at EUR 1.80 per share

Basel, 26.10.2006 - Lonza Group, the global life sciences company, today announces that the offer price for its subsidiary the Polynt S.p.A. IPO has been set.

- Offer price set at EUR 1.80 per share, identical for the retail and institutional tranches
- Implied initial market capitalization for Polynt S.p.A. of EUR 186m
- Polynt S.p.A. will have 103.2m shares outstanding
- The Global Offering was comprised of a base deal of 61.9m shares and an over-allotment option of 9.3m shares
- The free float pre the exercise of the over-allotment option will be 60%
- Lonza will receive EUR 111.5m in gross proceeds and retains a 40% stake in Polynt pre the exercise of the over-allotment option
- Listing and trading of Polynt S.p.A. shares to commence on the STAR segment of the Mercato Telematico Azionario (Electronic Stock Market) of the Borsa Italiana SpA on Monday 30 October, under the symbol PLY.
- Mediobanca was sponsor of Polynt S.p.A. and Global Coordinator of the IPO, and Merrill Lynch International was Co-Global Coordinator. Mediobanca and Merrill Lynch International were Joint Bookrunners on the transaction.

Polynt S.p.A., operates in the development, manufacture and marketing of polymers, chemical intermediates and additives used for a wide range of industrial applications including the manufacture of plastics, paints, inks, adhesives, electrical and electronic components, paper and lubricants, as well as resins and composites for the transportation and construction industries.

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life sciences industries. Its products and services span its customers' needs from research to final product manufacture. Lonza is the global leader in the production and support of pharmaceutical active ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agrochemical and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. The company employs 6,450 people and operates 25 production and R&D sites around the world, all operating to national and international quality standards (e.g. ISO) and regulations (e.g. cGMP). In 2005 Lonza had sales of CHF 2.52 billion. Further information can be found at www.lonza.com.

For further information:

Investor/Analyst enquiries:

Lonza

Margot Connor

Tel +41 61 316 8566

Fax +41 61 316 9566

Mobile +41 79 401 2832

margot.connor@lonza.com

Media:

Citigate Dewe Rogerson

Michael Berkeley

Tel +44 20 7638 9571

This press release is not an offer of securities for sale in the United States. The securities discussed herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. No public offering of the securities discussed herein is being made in the United States and the information contained herein does not constitute an offering of securities for sale in the United States, Canada, Australia or Japan. No money, securities or other consideration is being solicited and, if sent in response to the information contained herein, will not be accepted. This press release is an advertisement and not a prospectus and investors should not subscribe for or purchase any securities referred to in this press release except on the basis of the final prospectus to be published by the issuer in due course. This press release is only addressed to and directed at persons in member states of the European Economic Area who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC) ("Qualified Investors"). This press release does not constitute or form part of any offer or invitation to sell, or any solicitation of any offer to purchase, nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with, any contract therefore. This press release must not be acted on or relied on in any member state of the European Economic Area by persons who are not Qualified Investors. Any investment or investment activity to which this press release relates is available only to Qualified Investors in any member state of the European Economic Area, and will be engaged in only with such persons.